Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway
Journal of Cancer Research and Clinical Oncology · 07.03.2025 · 151 (3)
DOI: 10.1007/s00432-025-06154-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 07.03.2025. Verfasst von Can Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510055, People's Republic of China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Mouth Neoplasms, Carcinoma, Squamous Cell, p38 Mitogen-Activated Protein Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510055, People's Republic of China.
- Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, 510080, People's Republic of China.
- Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510055, People's Republic of China. chengbin@mail.sysu.edu.cn.
- Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, 510080, People's Republic of China. chengbin@mail.sysu.edu.cn.
- Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, 510055, People's Republic of China. huangyulei@mail.sysu.edu.cn.
- Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, 510080, People's Republic of China. huangyulei@mail.sysu.edu.cn.
Förderung
- the Science and Technology Program of Guangzhou
Zitieren
APA
Wang, C., Wu, Z., Zhou, J., Cheng, B., & Huang, Y. (2025). Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. Journal of Cancer Research and Clinical Oncology, 151(3). https://doi.org/10.1007/s00432-025-06154-5
Vancouver
Wang C, Wu Z, Zhou J, Cheng B, Huang Y. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. Journal of Cancer Research and Clinical Oncology. 2025;151(3). doi:10.1007/s00432-025-06154-5
BibTeX
@article{Wang2025,
author = {Wang, Can and Wu, Zhengzheng and Zhou, Jiaying and Cheng, Bin and Huang, Yulei},
title = {Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
volume = {151},
number = {3},
doi = {10.1007/s00432-025-06154-5}
}
EUVIMED